<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?properties manuscript?><?origin nihpa?><?iso-abbr Leukemia?><?submitter-system nihms?><?submitter-canonical-name Nature Publishing Group?><?submitter-canonical-id NATURE-STRUCTUR?><?submitter-userid 1045?><?submitter-authority publisher?><?submitter-login nature-structure?><?submitter-name Nature Publishing Group (obsolete)?><?domain nihpa?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">8704895</journal-id><journal-id journal-id-type="pubmed-jr-id">5536</journal-id><journal-id journal-id-type="nlm-ta">Leukemia</journal-id><journal-id journal-id-type="iso-abbrev">Leukemia</journal-id><journal-title-group><journal-title>Leukemia</journal-title></journal-title-group><issn pub-type="ppub">0887-6924</issn><issn pub-type="epub">1476-5551</issn></journal-meta><article-meta><article-id pub-id-type="pmcid">4351165</article-id><article-id pub-id-type="pmid">25204569</article-id><article-id pub-id-type="doi">10.1038/leu.2014.267</article-id><article-id pub-id-type="manuscript">nihpa624934</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Prognostic and biologic significance of <italic>DNMT3B</italic> expression in older patients with cytogenetically normal primary acute myeloid leukemia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Niederwieser</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kohlschmidt</surname><given-names>Jessica</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Volinia</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Whitman</surname><given-names>Susan P.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Metzeler</surname><given-names>Klaus H.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Eisfeld</surname><given-names>Ann-Kathrin</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Maharry</surname><given-names>Kati</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Pearlly</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Frankhouser</surname><given-names>David</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Becker</surname><given-names>Heiko</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schwind</surname><given-names>Sebastian</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Carroll</surname><given-names>Andrew J.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Nicolet</surname><given-names>Deedra</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mendler</surname><given-names>Jason H.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Curfman</surname><given-names>John P.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Yue-Zhong</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Baer</surname><given-names>Maria R.</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Powell</surname><given-names>Bayard L.</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Kolitz</surname><given-names>Jonathan E.</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Moore</surname><given-names>Joseph O.</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Carter</surname><given-names>Thomas H.</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Bundschuh</surname><given-names>Ralf</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Larson</surname><given-names>Richard A.</given-names></name><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Stone</surname><given-names>Richard M.</given-names></name><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><name><surname>Mr&#x000f3;zek</surname><given-names>Krzysztof</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="author-notes" rid="FN1">*</xref></contrib><contrib contrib-type="author"><name><surname>Marcucci</surname><given-names>Guido</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="author-notes" rid="FN1">*</xref></contrib><contrib contrib-type="author"><name><surname>Bloomfield</surname><given-names>Clara D.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="author-notes" rid="FN1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>The Ohio State University Comprehensive Cancer Center, Columbus, OH</aff><aff id="A2"><label>2</label>Alliance for Clinical Trials in Oncology Statistics and Data Center, Mayo Clinic, Rochester, MN</aff><aff id="A3"><label>3</label>University of Alabama at Birmingham, Birmingham, AL</aff><aff id="A4"><label>4</label>Greenebaum Cancer Center, University of Maryland, Baltimore, MD</aff><aff id="A5"><label>5</label>Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC</aff><aff id="A6"><label>6</label>Monter Cancer Center, Hofstra North Shore-Long Island Jewish School of Medicine, Lake Success, NY</aff><aff id="A7"><label>7</label>Duke University Medical Center, Durham, NC</aff><aff id="A8"><label>8</label>University of Iowa, Iowa City, IA</aff><aff id="A9"><label>9</label>Departments of Physics and Chemistry &#x00026; Biochemistry, The Ohio State University, Columbus, OH</aff><aff id="A10"><label>10</label>University of Chicago Medical Center, Chicago, IL</aff><aff id="A11"><label>11</label>Dana Farber Cancer Institute, Boston, MA</aff><author-notes><corresp id="cor1">Correspondence: Clara D. Bloomfield, MD, The Ohio State University Comprehensive Cancer Center, 1216 James Cancer Hospital, 300 West Tenth Avenue, Columbus, OH 43210-1228. <email>clara.bloomfield@osumc.edu</email>; or Guido Marcucci, MD, The Ohio State University Comprehensive Cancer Center, 410 Biomedical Research Tower, 460 West Twelfth Avenue, Columbus, OH 43210. <email>guido.marcucci@osumc.edu</email>; or Krzysztof Mr&#x000f3;zek, MD, PhD, The Ohio State University Comprehensive Cancer Center, 1232A James Cancer Hospital, 300 West Tenth Avenue, Columbus, OH 43210-1228. <email>krzysztof.mrozek@osumc.edu</email></corresp><fn id="FN1" fn-type="equal"><label>*</label><p id="P1">These senior authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>3</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>10</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>9</month><year>2015</year></pub-date><volume>29</volume><issue>3</issue><fpage>567</fpage><lpage>575</lpage><!--elocation-id from pubmed: 10.1038/leu.2014.267--><permissions><license xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms"><license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:<ext-link ext-link-type="uri" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</ext-link></license-p></license></permissions><abstract><p id="P2"><italic>DNMT3B</italic> encodes a DNA methyltransferase implicated in aberrant epigenetic changes contributing to leukemogenesis. We tested whether <italic>DNMT3B</italic> expression, measured by NanoString nCounter assay, associates with outcome, gene- and microRNA-expression and DNA methylation profiles in 210 older (&#x02265;60 years) adults with primary, cytogenetically normal AML (CN-AML). Patients were dichotomized into high versus low expressers using median cut. Outcomes were assessed in the context of known CN-AML prognosticators. Gene- and microRNA-expression, and DNA methylation profiles were analyzed using microarrays and MethylCap-sequencing, respectively. High <italic>DNMT3B</italic> expressers had fewer complete remissions (CR; <italic>P</italic>=0.002) and shorter disease-free (DFS; <italic>P</italic>=0.02) and overall (OS; <italic>P</italic>&#x0003c;0.001) survival. In multivariable analyses, high <italic>DNMT3B</italic> expression remained an independent predictor of lower CR rates (<italic>P</italic>=0.04) and shorter DFS (<italic>P</italic>=0.04) and OS (<italic>P</italic>=0.001). High <italic>DNMT3B</italic> expression associated with a gene-expression profile comprising 363 genes involved in differentiation, proliferation and survival pathways, but with only 4 differentially expressed microRNAs (<italic>miR-133b</italic>, <italic>miR-148a</italic>, <italic>miR-122,</italic><italic>miR-409-3p</italic>) and no differential DNA methylation regions. We conclude that high <italic>DNMT3B</italic> expression independently associates with adverse outcome in older CN-AML patients. Gene-expression analyses suggest that <italic>DNMT3B</italic> is involved in the modulation of several genes, although the regulatory mechanisms remain to be investigated to devise therapeutic approaches specific for these patients.</p></abstract><kwd-group><kwd>acute myeloid leukemia</kwd><kwd><italic>DNMT3B</italic> expression</kwd><kwd>prognostication</kwd><kwd>gene-expression profiling</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S1"><title>INTRODUCTION</title><p id="P3">Acute myeloid leukemia (AML) is a heterogeneous disease presenting with a wide spectrum of prognostically relevant cytogenetic aberrations, gene mutations and abnormal expression of genes and microRNAs. Cytogenetically normal AML (CN-AML) patients, constituting 40 to 50% of all AML patients,<sup><xref rid="R1" ref-type="bibr">1</xref></sup> are the largest and molecularly best characterized cytogenetic subset in primary (<italic>de novo</italic>) AML.<sup><xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R3" ref-type="bibr">3</xref></sup> Although leukemic blasts of these patients do not contain microscopically detectable chromosome abnormalities, they harbor prognostically relevant mutations and aberrantly expressed genes and microRNAs.<sup><xref rid="R2" ref-type="bibr">2</xref>&#x02013;<xref rid="R16" ref-type="bibr">16</xref></sup> In addition to these genetic alterations, epigenetic changes have recently been shown to participate in myeloid leukemogenesis and be pharmacologically targetable.<sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup> Notably, some genes whose mutations are prognostic in CN-AML encode proteins that are implicated in epigenetic regulation of gene transcription, namely <italic>IDH2, ASXL1</italic> and <italic>DNMT3A.</italic> The latter is among the most frequently mutated genes in primary CN-AML patients, being found mutated in 29 to 34% of the patients.<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup></p><p id="P4"><italic>DNMT3A</italic> encodes DNA methyltransferase 3A (DNMT3A), which is involved in epigenetic gene silencing through DNA hypermethylation.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> In addition to DNMT3A, DNMT1 and DNMT3B also mediate DNA methylation in normal and malignant cells, and may represent potential therapeutic targets in cancer and leukemia.<sup><xref rid="R21" ref-type="bibr">21</xref>&#x02013;<xref rid="R24" ref-type="bibr">24</xref></sup> However, in contrast to <italic>DNMT3A</italic>, no recurrent mutations of <italic>DNMT1</italic> and <italic>DNMT3B</italic> genes have been reported in AML.<sup><xref rid="R25" ref-type="bibr">25</xref></sup> Instead, one study has indicated that higher expression of <italic>DNMT3B</italic> is associated with worse outcome in AML.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> However, the patient cohort analyzed was cytogenetically diverse and heterogeneous for clinical features and treatment received. Thus, it is unknown whether <italic>DNMT3B</italic> expression is an independent prognostic factor and can be used for stratification guidance in CN-AML.</p><p id="P5">Thus, we analyzed the clinical significance of <italic>DNMT3B</italic> expression in the context of a comprehensive panel of molecular prognosticators in a relatively large cohort of older (aged &#x02265;60 years) patients with CN-AML who were similarly treated on cytarabine/daunorubicin-based protocols. To gain biologic insights, we also derived genome-wide <italic>DNMT3B</italic>-associated gene- and microRNA-expression and DNA methylation profiles. We studied older patients because both the incidence of AML and the role of epigenetics increase with age. Moreover, we have recently reported a favorable clinical response to hypomethylating agents in this age group of AML patients.<sup><xref rid="R27" ref-type="bibr">27</xref></sup></p></sec><sec sec-type="subjects|methods" id="S2"><title>PATIENTS AND METHODS</title><sec id="S3"><title>Patients, treatment and cytogenetic studies</title><p id="P6">Pretreatment bone marrow (BM) or blood samples were obtained from 210 patients with primary CN-AML aged 60 to 83 years (median, 68 years) who received intensive first-line therapy on Cancer and Leukemia Group B (CALGB) trials.<sup><xref rid="R28" ref-type="bibr">28</xref>&#x02013;<xref rid="R32" ref-type="bibr">32</xref></sup> All patients received cytarabine-daunorubicin-based induction chemotherapy, and no patient received allogeneic hematopoietic stem cell transplantation (HSCT) during first complete remission (CR). For details regarding treatment protocols and sample collection, see <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>. All patients were enrolled on companion CALGB/Alliance protocols: 8461 (cytogenetic analyses), 9665 (tissue banking) and 20202 (molecular analyses).</p><p id="P7">Cytogenetic analyses were performed in institutional CALGB/Alliance cytogenetics laboratories. For the patient&#x02019;s karyotype to be considered normal, &#x02265;20 metaphase cells from short-term cultures of pretreatment BM specimens had to have been analyzed and the normal result confirmed by central karyotype review.<sup><xref rid="R33" ref-type="bibr">33</xref></sup> All patients provided written informed consent for participation in these studies; study protocols were in accordance with the Declaration of Helsinki and approved by local Institutional Review Boards.</p></sec><sec id="S4"><title>Single-gene expression analyses</title><p id="P8">The expression of <italic>DNMT3B</italic> transcript was assessed by NanoString nCounter assays (NanoString Technologies, Seattle, WA, USA; <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>).<sup><xref rid="R34" ref-type="bibr">34</xref></sup> These assays measured global expression of the <italic>DNMT3B</italic> gene, and did not allow for quantification of isoform-specific expression of <italic>DNMT3B</italic>. <italic>DNMT3B</italic> expression levels were normalized using <italic>ABL</italic> as an internal control. We also used NanoString nCounter assays to measure expression of <italic>BAALC</italic>, <italic>ERG</italic> and <italic>miR-155</italic>, and real-time RT-PCR to measure <italic>miR-3151</italic> expression, all of which have been previously shown to affect prognosis of older CN-AML patients.<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref></sup></p></sec><sec id="S5"><title>Mutational analyses</title><p id="P9">The presence or absence of <italic>FLT3</italic> internal tandem duplication (<italic>FLT3</italic>-ITD),<sup><xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R36" ref-type="bibr">36</xref></sup>
<italic>FLT3</italic> tyrosine kinase domain mutations (<italic>FLT3</italic>-TKD),<sup><xref rid="R37" ref-type="bibr">37</xref></sup>
<italic>MLL</italic> partial tandem duplication (<italic>MLL</italic>-PTD),<sup><xref rid="R38" ref-type="bibr">38</xref></sup> and mutations in the <italic>NPM1</italic>,<sup><xref rid="R5" ref-type="bibr">5</xref></sup>
<italic>CEBPA</italic>,<sup><xref rid="R39" ref-type="bibr">39</xref></sup>
<italic>WT1</italic>,<sup><xref rid="R40" ref-type="bibr">40</xref></sup>
<italic>IDH1</italic> and <italic>IDH2</italic>,<sup><xref rid="R7" ref-type="bibr">7</xref></sup>
<italic>TET2</italic>,<sup><xref rid="R41" ref-type="bibr">41</xref></sup>
<italic>ASXL1</italic>,<sup><xref rid="R8" ref-type="bibr">8</xref></sup>
<italic>DNMT3A</italic><sup><xref rid="R9" ref-type="bibr">9</xref></sup> and <italic>RUNX1</italic><sup><xref rid="R42" ref-type="bibr">42</xref></sup> genes were determined centrally as previously described.</p></sec><sec id="S6"><title>Gene- and microRNA-expression profiling</title><p id="P10">The gene- and microRNA-expression profiling were assessed using the Affymetrix U133 plus 2.0 array (Affymetrix, Santa Clara, CA) and The Ohio State University (OSU) custom microRNA array (OSU_CCC Version 4.0), respectively, as previously reported,<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R43" ref-type="bibr">43</xref></sup> and detailed in the <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>. For <italic>DNMT3B</italic>, the Affymetrix U133 plus 2.0 arrays measured global <italic>DNMT3B</italic> expression levels, and did not quantify expression of the individual <italic>DNMT3B</italic> isoforms. For the gene- and microRNA-expression profiling, summary measures of gene and microRNA expression were computed, normalized, and filtered (<xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>). A <italic>DNMT3B</italic> expression-associated signature (see <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref> for details) was derived by comparing gene expression between high and low <italic>DNMT3B</italic> expressers in the Alliance cohort and in two additional sets of CN-AML patients with microarray and RNAseq gene expression data publicly available [German AML Cooperative Group (AMLCG)<sup><xref rid="R44" ref-type="bibr">44</xref></sup> and The Cancer Genome Atlas (TCGA)<sup><xref rid="R25" ref-type="bibr">25</xref></sup>]. For comparison of the high <italic>DNMT3B</italic> expression signature with the <italic>FLT3</italic>-ITD signature we used gene set enrichment analysis (GSEA; for details see <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>). For the microRNA expression signature, only the CALGB/Alliance patients were used. Univariable significance levels of <italic>P</italic>&#x0003c;0.001 (false discovery rates (FDR) &#x0003c;0.01) were used to select genes and microRNAs that constituted the signatures. To assess enrichment of genes in the <italic>DNMT3B</italic> gene-expression-associated signature in distinct biologic processes, a Gene Ontology (GO) analysis was performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID).<sup><xref rid="R45" ref-type="bibr">45</xref></sup> We identified as statistically significant &#x0201c;annotation clusters&#x0201d; those clusters of GO terms with enrichment scores of &#x0003e;2.0, <italic>P</italic>-values &#x02264;0.001 and Benjamini corrected <italic>P</italic>-values &#x02264;0.05. All molecular analyses were performed centrally at OSU.</p></sec><sec id="S7"><title>DNA methylation</title><p id="P11">Genome-wide DNA methylation and levels of DNA methylation across the genome&#x02019;s functional regions (i.e., genomic features) were measured using the MethylCap-seq assay as previously reported.<sup><xref rid="R18" ref-type="bibr">18</xref></sup></p></sec><sec id="S8"><title>Statistical analyses</title><p id="P12">The patients were dichotomized into high and low expressers using the median cut. This cut was supported by significant results of the trend test applied to outcome of patients divided into quartiles by <italic>DNMT3B</italic> expression (<italic>P</italic>&#x02264;0.001). We compared pretreatment features and outcome between patients with high and low <italic>DNMT3B</italic> expression. Definitions of clinical endpoints [i.e., CR rates, disease-free (DFS) and overall (OS) survival] are provided in the <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>. Baseline characteristics between high and low <italic>DNMT3B</italic> expressers were compared using the Fisher&#x02019;s exact test for categorical and the Wilcoxon rank-sum test for continuous variables.<sup><xref rid="R46" ref-type="bibr">46</xref></sup> The categorical variables included the European LeukemiaNet (ELN) Genetic Groups.<sup><xref rid="R47" ref-type="bibr">47</xref></sup> The ELN guidelines classify CN-AML patients within the Favorable or Intermediate-I Genetic Groups based on <italic>CEBPA, NPM1</italic> and <italic>FLT3</italic> mutational status. The ELN Favorable Genetic Group consists of CN-AML patients with <italic>CEBPA</italic> mutation and/or <italic>NPM1</italic> mutation without <italic>FLT3</italic>-ITD, whereas the Intermediate-I Genetic Group is comprised of patients with wild-type <italic>CEBPA</italic> and <italic>FLT3</italic>-ITD with or without <italic>NPM1</italic> mutation, or wild-type <italic>NPM1</italic> without <italic>FLT3</italic>-ITD.<sup><xref rid="R47" ref-type="bibr">47</xref></sup></p><p id="P13">For time-to-event analyses, we calculated survival estimates using the Kaplan-Meier method, and compared groups by the log-rank test.<sup><xref rid="R46" ref-type="bibr">46</xref></sup> In order to provide the odds ratios and hazard ratios and associated confidence intervals, logistic regression and Cox proportional hazards models were generated to compare outcomes between high and low <italic>DNMT3B</italic> expressers for CR and survival endpoints (DFS, OS), respectively, and <italic>P</italic>-values from the Wald test are reported. We constructed multivariable logistic regression models to analyze factors associated with the achievement of CR, and multivariable Cox proportional hazards models for factors associated with survival endpoints,<sup><xref rid="R46" ref-type="bibr">46</xref></sup> the details of which are provided in the <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>. All analyses were performed by the Alliance for Clinical Trials in Oncology Statistics and Data Center.</p></sec></sec><sec sec-type="results" id="S9"><title>RESULTS</title><sec id="S10"><title>Associations of DNMT3B expression with pretreatment clinical and molecular characteristics</title><p id="P14">At diagnosis, high <italic>DNMT3B</italic> expressers had higher white blood counts (WBC; <italic>P</italic>=0.004), and percentages of blood (<italic>P</italic>=0.004) and marrow (<italic>P</italic>=0.02) blasts than low <italic>DNMT3B</italic> expressers. Concerning molecular features, high <italic>DNMT3B</italic> expressers were more often <italic>FLT3</italic>-ITD-positive (<italic>P</italic>&#x0003c;0.001) and classified in the ELN Intermediate-I Genetic Group (<italic>P</italic>=0.02). <italic>IDH2</italic>-R140 mutations were less frequent in high <italic>DNMT3B</italic> expressers, whereas six of seven <italic>IDH2</italic>-R172 mutations were detected in this patient group. High <italic>DNMT3B</italic> expressers also had higher <italic>ERG</italic> (<italic>P</italic>&#x0003c;0.001), <italic>BAALC</italic> (<italic>P</italic>=0.002) and <italic>miR-155</italic> (<italic>P</italic>=0.006) expression than low expressers (<xref ref-type="table" rid="T1">Table 1</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S1</xref>).</p></sec><sec id="S11"><title>Associations of DNMT3B expression with clinical outcome in the entire patient cohort</title><p id="P15">With a median follow-up for patients alive of 5.1 years (range, 2.3&#x02013;11.6 years), high <italic>DNMT3B</italic> expressers had lower CR rates (<italic>P</italic>=0.002, Wald test; 58% vs 78%), and shorter DFS (<italic>P</italic>=0.02, Wald test) and OS (<italic>P</italic>&#x0003c;0.001, Wald test) than <italic>DNMT3B</italic> low expressers (<xref ref-type="table" rid="T2">Table 2</xref>, <xref ref-type="fig" rid="F1">Figure 1</xref>).</p><p id="P16">In a multivariable model for CR, <italic>DNMT3B</italic> expression remained prognostic (<italic>P</italic>=0.04), after adjustment for <italic>BAALC</italic> expression status (<italic>P</italic>&#x0003c;0.001), WBC (<italic>P</italic>=0.007) and age (<italic>P</italic>=0.02) (<xref ref-type="table" rid="T3">Table 3</xref>). High <italic>DNMT3B</italic> expressers were half as likely to achieve a CR as low expressers. In multivariable analysis for DFS, high <italic>DNMT3B</italic> expression associated with shorter DFS (<italic>P</italic>=0.04), once adjusted for <italic>BAALC</italic> expression (<italic>P</italic>=0.004), <italic>DNMT3A</italic>-R882 mutation status (<italic>P</italic>=0.009) and ELN Genetic Groups (<italic>P</italic>=0.03). The risk of experiencing relapse or death was 46% higher for high <italic>DNMT3B</italic> expressers than for low expressers. <italic>DNMT3B</italic> expression also remained prognostic for OS (<italic>P</italic>=0.001), after adjustment for <italic>BAALC</italic> expression (<italic>P</italic>&#x0003c;0.001), <italic>miR-3151</italic> (<italic>P</italic>=0.02) and <italic>miR-155</italic> (<italic>P</italic>=0.02). The risk of death was 72% higher for high <italic>DNMT3B</italic> expressers compared with low expressers (<xref ref-type="table" rid="T3">Table 3</xref>).</p></sec><sec id="S12"><title>Associations of DNMT3B expression with clinical outcome in ELN genetic groups</title><p id="P17">We analyzed the associations of <italic>DNMT3B</italic> expression with outcome separately within the ELN Favorable and Intermediate-I Genetic Groups. Within the Favorable Group (n=94), there was no significant difference in CR rates (71% vs 84%, <italic>P</italic>=0.14, Wald test) or DFS (<italic>P</italic>=0.10, Wald test) between high and low <italic>DNMT3B</italic> expressers. However, high expressers had shorter OS (<italic>P</italic>=0.002, Wald test) than low expressers (<xref ref-type="table" rid="T2">Table 2</xref>, <xref ref-type="fig" rid="F2">Figures 2A and 2B</xref>). In multivariable analyses for the ELN Favorable Genetic Group (<xref ref-type="table" rid="T3">Table 3</xref>), <italic>DNMT3B</italic> expression remained significant for OS (<italic>P</italic>=0.003) after adjustment for <italic>BAALC</italic> expression (<italic>P</italic>=0.01). High <italic>DNMT3B</italic> expressers were twice as likely to die as low expressers.</p><p id="P18">In the Intermediate-I Group (n=108), high <italic>DNMT3B</italic> expressers had a lower CR rate (49% vs 73%, <italic>P</italic>=0.01, Wald test) and shorter OS (<italic>P</italic>=0.03, Wald test) than low <italic>DNMT3B</italic> expressers, but there was no significant difference in DFS between the groups (<xref ref-type="table" rid="T2">Table 2</xref>, <xref ref-type="fig" rid="F2">Figures 2C and 2D</xref>). In multivariable analyses within the ELN Intermediate-I Genetic Group (<xref ref-type="table" rid="T3">Table 3</xref>), <italic>DNMT3B</italic> expression was significant for OS (<italic>P</italic>=0.02), after adjustment for <italic>BAALC</italic> expression (<italic>P</italic>=0.03), <italic>miR-3151</italic> expression (<italic>P</italic>=0.03) and WBC (<italic>P</italic>=0.03). High <italic>DNMT3B</italic> expressers were 1.7 times more likely to die than low expressers.</p></sec><sec id="S13"><title>Genome-wide gene-expression profiles associated with DNMT3B expression</title><p id="P19">To gain biologic insights into the role of <italic>DNMT3B</italic>, we derived a <italic>DNMT3B</italic>-associated gene-expression profile using three independent sets of CN-AML patients, i.e., CALGB/Alliance (n=177), AMLCG (n=75) and TCGA (n=88). We identified 195 upregulated genes and 168 downregulated genes that were significantly associated with higher <italic>DNMT3B</italic> expression in each of the three cohorts (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table S1</xref>). Since high <italic>DNMT3B</italic> expression was associated with the presence of <italic>FLT3</italic>-ITD (<xref ref-type="table" rid="T1">Table 1</xref>), we performed GSEA to test whether a set of 195 genes that are upregulated in high <italic>DNMT3B</italic> expressers is associated with a set of genes differentially expressed between patients who harbored <italic>FLT3</italic>-ITD versus those who did not (<xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>). We found a significant correlation between the high <italic>DNMT3B</italic> expression and <italic>FLT3</italic>-ITD signatures (<italic>P</italic>=0.006; FDR=0.006; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S2</xref>). Among the genes upregulated in high <italic>DNMT3B</italic> expressers, we noted a variety of genes previously involved in AML including <italic>CDK6</italic> and <italic>WT1</italic> that encode cyclin kinase and transcription factor proteins, respectively. Among the downregulated genes, we noted genes involved with both normal monocyte/macrophage differentiation and immune function including <italic>CD14</italic>, <italic>TLR4, CEBPB</italic> and <italic>TLR8</italic>.</p><p id="P20">Gene Ontology was used to assess the biologic features of the <italic>DNMT3B</italic>-expression profile (<xref ref-type="table" rid="T4">Table 4</xref>). For <italic>DNMT3B</italic>-associated upregulated genes, there were three GO terms comprising genes involved in nucleotide biosynthetic processes and metabolism and included in annotation cluster 1 that had a trend for statistical significance (Benjamini <italic>P</italic>-value &#x0003c;0.1). For <italic>DNMT3B</italic>-associated downregulated genes, cellular processes included lysosome biology, endocytosis and membrane signaling. These results may be interpreted as consistent with the previously noted dysregulated genes involved in monocyte/macrophage differentiation and activity.</p></sec><sec id="S14"><title>Genome-wide microRNA profiles associated with DNMT3B expression</title><p id="P21">The influence of <italic>DNMT3B</italic> expression on microRNA genome-wide profiles could be evaluated in 162 patients. In contrast to coding genes, only four microRNAs were differentially expressed between high and low <italic>DNMT3B</italic> expressers (<italic>P</italic>&#x02264;0.001). High <italic>DNMT3B</italic> expression was associated with <italic>miR-133b</italic> upregulation, and <italic>miR-148a</italic>, <italic>miR-122</italic> and <italic>miR-409-3p</italic> downregulation. <italic>miR-133b</italic> upregulation in high <italic>DNMT3B</italic> expressers was somewhat surprising as this microRNA was reported to have tumor suppressor activity in other cancers.<sup><xref rid="R48" ref-type="bibr">48</xref>,<xref rid="R49" ref-type="bibr">49</xref></sup> However, consistent with the downregulated gene-expression profile discussed above, <italic>miR-133b</italic> has recently been shown to target GM-CSF, a cytokine involved in granulocyte-monocyte/macrophage differentiation.<sup><xref rid="R50" ref-type="bibr">50</xref></sup> Among the downregulated microRNAs, <italic>miR-148a</italic> was reported to target <italic>DNMT3B</italic> and to be itself a target of aberrant hypermethylation in cancer.<sup><xref rid="R51" ref-type="bibr">51</xref>,<xref rid="R52" ref-type="bibr">52</xref></sup> Lower expression of <italic>miR-122</italic> has been associated with aggressive hepatocellular carcinoma and <italic>miR-409-3p</italic> with cell invasion and metastasis in gastric cancer<sup><xref rid="R53" ref-type="bibr">53</xref>&#x02013;<xref rid="R56" ref-type="bibr">56</xref></sup>; however, a role for these microRNAs in AML is currently unknown.</p></sec><sec id="S15"><title>Genome-wide methylation profiling associated with DNMT3B expression</title><p id="P22">Since <italic>DNMT3B</italic> encodes a methyltransferase that mediates <italic>de novo</italic> DNA methylation, we assessed whether high and low <italic>DNMT3B</italic> expressers differed in DNA methylation patterns. Surprisingly, we found no significant differences in genome-wide DNA methylation levels or in the numbers of differentially methylated regions (DMRs)<sup><xref rid="R18" ref-type="bibr">18</xref></sup> in distinct functional genomic regions (e.g., gene promoters) when high versus low <italic>DNMT3B</italic> expressers were compared.</p></sec></sec><sec sec-type="discussion" id="S16"><title>DISCUSSION</title><p id="P23">In this study, we report that high <italic>DNMT3B</italic> expression associates with lower CR rates and shorter DFS and OS in chemotherapy-treated CN-AML patients aged &#x02265;60 years. High <italic>DNMT3B</italic> expression was associated with such adverse prognostic factors as <italic>FLT3</italic>-ITD, high <italic>ERG</italic>, <italic>BAALC</italic> and <italic>miR-155</italic> expression and the ELN Intermediate-I Genetic Group; nevertheless the association of <italic>DNMT3B</italic> expression with clinical outcome is independent from the aforementioned and other established molecular and clinical prognosticators for all outcome endpoints studied.</p><p id="P24">Our findings are consistent to some extent with the only, to our knowledge, previous study that assessed the prognostic value of <italic>DNMT3B</italic> expression.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> Although in the subset of 93 CN-AML patients, Hayette <italic>et al</italic>.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> did not find significant differences in event-free survival (EFS) or OS between high and low <italic>DNMT3B</italic> expressers, high <italic>DNMT3B</italic> expressers had a shorter EFS than low <italic>DNMT3B</italic> expressers in the whole cytogenetically diverse cohort of 191 AML patients analyzed. It is difficult to directly compare their results with ours since approximately one-half of the patients analyzed by Hayette <italic>et al</italic>.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> had various abnormal karyotypes, more than two-thirds of the patients were younger than 60 years and a quarter underwent allogeneic HSCT in first CR. Thus, although the two studies are not comparable, they both conclude that higher <italic>DNMT3B</italic> expression is associated with worse outcome in AML.</p><p id="P25">Recently, the ELN Reporting System,<sup><xref rid="R47" ref-type="bibr">47</xref></sup> which for CN-AML is based on only three molecular markers (i.e., <italic>FLT3</italic>-ITD, <italic>CEBPA</italic> and <italic>NPM1</italic> mutations), was shown to provide important prognostic information in AML.<sup><xref rid="R57" ref-type="bibr">57</xref></sup> However, we and others have shown that additional molecular markers, such as <italic>TET2</italic>,<sup><xref rid="R41" ref-type="bibr">41</xref></sup>
<italic>ASXL1</italic>,<sup><xref rid="R8" ref-type="bibr">8</xref></sup>
<italic>RUNX1</italic><sup><xref rid="R42" ref-type="bibr">42</xref></sup> and <italic>DNMT3A</italic><sup><xref rid="R58" ref-type="bibr">58</xref></sup> mutations and expression of <italic>MN1</italic>,<sup><xref rid="R12" ref-type="bibr">12</xref></sup>
<italic>miR-155</italic><sup><xref rid="R15" ref-type="bibr">15</xref></sup> and <italic>miR-3151</italic>,<sup><xref rid="R16" ref-type="bibr">16</xref></sup> may refine outcome prediction of CN-AML patients within the ELN Genetic Groups. Hence, in the current study, we investigated whether considering <italic>DNMT3B</italic> expression as a novel prognosticator could alter patient classification within the ELN Genetic Groups. In the Favorable Group, we found that low <italic>DNMT3B</italic> expression identified a subset of CN-AML patients with a significantly longer OS, thus making <italic>DNMT3B</italic> expression the third molecular marker, in addition to <italic>ASXL1</italic> mutations<sup><xref rid="R8" ref-type="bibr">8</xref></sup> and <italic>miR-155</italic> expression,<sup><xref rid="R15" ref-type="bibr">15</xref></sup> capable of refining prognostication of older patients in this ELN Genetic Group. We also observed a significant difference in OS between high and low <italic>DNMT3B</italic> expressers classified in the ELN Intermediate-I Genetic Group. Previously, <italic>RUNX1</italic> mutations<sup><xref rid="R42" ref-type="bibr">42</xref></sup> and expression levels of <italic>MN1</italic>,<sup><xref rid="R12" ref-type="bibr">12</xref></sup>
<italic>miR-155</italic><sup><xref rid="R15" ref-type="bibr">15</xref></sup> and <italic>miR-3151</italic><sup><xref rid="R16" ref-type="bibr">16</xref></sup> were demonstrated to add prognostic information in this ELN Genetic Group.</p><p id="P26">We report the first, to our knowledge, <italic>DNMT3B</italic>-associated gene- and microRNA-expression and DNA methylation profiles in CN-AML. We were able to derive a strong gene expression profile comprising 363 genes by overlapping the microarray results from three independent sets of patients. The profile was quite heterogeneous, comprising genes encoding for proteins involved in multiple biologic processes that play a role in leukemia cell differentiation, proliferation and survival. Among the downregulated genes, we noted enrichment of genes involved in monocyte/macrophage differentiation and activity, suggesting a role of <italic>DNMT3B</italic> in impairing differentiation of the leukemic blasts into cells with normal innate immunity activity. Using GSEA, we found a significant correlation between the high <italic>DNMT3B</italic> expression and <italic>FLT3</italic>-ITD signatures (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S2</xref>). This, along with the increased frequency of <italic>FLT3</italic>-ITD in high <italic>DNMT3B</italic> expressers (<xref ref-type="table" rid="T1">Table 1</xref>), suggests the existence of a functional association between high expression of the <italic>DNMT3B</italic> gene and <italic>FLT3</italic>-ITD.</p><p id="P27">In contrast, the <italic>DNMT3B</italic>-associated microRNA profile was relatively weak, comprising only four microRNAs that were differentially expressed in high versus low <italic>DNMT3B</italic> expressers. Nevertheless, the unique upregulation of expression of <italic>miR-133b</italic>, recently reported to target GM-CSF,<sup><xref rid="R50" ref-type="bibr">50</xref></sup> in <italic>DNMT3B</italic> high expressers was somewhat consistent with the enrichment of the gene-expression profile in multiple downregulated genes involved in the differentiation and activity of hematopoietic cells participating in innate immunity.</p><p id="P28">Surprisingly, despite the fact that <italic>DNMT3B</italic> encodes a DNA methyltransferase, we observed no significant association of high <italic>DNMT3B</italic> levels and DNA methylation changes. No difference in global DNA methylation levels and number of DMRs could be identified between <italic>DNMT3B</italic> high and low expressers. Our results are reminiscent of a recent report showing that changes in <italic>DNMT3B</italic> expression did not affect methylation levels of putative DNMT3B target genes.<sup><xref rid="R59" ref-type="bibr">59</xref></sup> Moreover, Russler-Germain <italic>et al</italic>.<sup><xref rid="R60" ref-type="bibr">60</xref></sup> have recently demonstrated that DNA methylation levels in leukemic blasts from CN-AML patients are not influenced by <italic>DNMT3B</italic> expression since mainly inactive splice variants of <italic>DNMT3B</italic> are expressed in these cells. Overall, therefore, these data may suggest that although overexpressed <italic>DNMT3B</italic> is a potentially valuable predictive marker for response to conventional chemotherapy, it does not necessarily identify subsets of older AML patients characterized by aberrant DNA methylation who might be responsive to hypomethylating azanucleosides.</p><p id="P29">In summary, we have demonstrated that <italic>DNMT3B</italic> expression constitutes an independent prognostic factor in older CN-AML patients treated intensively, and could also refine the ELN classification. Furthermore, we have provided some insights into the biologic activity of <italic>DNMT3B</italic> in CN-AML, which is seemingly independent from mechanisms of DNA hypermethylation and/or microRNA-dependent gene repression. Further studies focused on gaining more clinical and mechanistic insights into the leukemogenic role of <italic>DNMT3B</italic> expression are warranted to design active therapeutic strategies for high <italic>DNMT3B</italic> expressers in CN-AML.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>1</label><media xlink:href="NIHMS624934-supplement-1.docx" orientation="portrait" xlink:type="simple" id="d37e1616" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>2</label><media xlink:href="NIHMS624934-supplement-2.xlsx" orientation="portrait" xlink:type="simple" id="d37e1620" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD3"><label>3</label><media xlink:href="NIHMS624934-supplement-3.xlsx" orientation="portrait" xlink:type="simple" id="d37e1624" position="anchor"/></supplementary-material></sec></body><back><fn-group><fn id="FN2" fn-type="presented-at"><p id="P30">Presented in part at the 18<sup>th</sup> Congress of the European Hematology Association, Stockholm, Sweden, June 13&#x02013;16, 2013, and published in abstract form: Niederwieser C, Kohlschmidt J, Maharry K, Mr&#x000f3;zek K, Metzeler K, Volinia S <italic>et al</italic>. High expression of DNMT3B negatively impacts on clinical outcome of older patients (pts) with primary cytogenetically normal (CN) acute myeloid leukemia (AML) [CALGB 20202 (ALLIANCE)]. <italic>Haematologica</italic> 2013; <bold>98</bold>(suppl 1): 484 (abstract S1168).</p></fn><fn id="FN3" fn-type="conflict"><p id="P31"><bold>CONFLICT OF INTEREST</bold></p><p id="P32">The authors declare no conflict of interest.</p></fn><fn id="FN4" fn-type="con"><p id="P33"><bold>AUTHOR CONTRIBUTIONS</bold></p><p id="P34">CN, JK, SV, K Mr&#x000f3;zek, GM and CDB designed the study, analyzed the data and wrote the manuscript, and all authors agreed on the final version; SPW, KHM, A-KE, PY, DF HB, SS, JHM, JPC, Y-ZW, and RB carried out laboratory-based research; JK, K Maharry, SV, and DN performed statistical analyses; and AJC, MRB, BLP, JEK, JOM, THC, RAL, RMS, K Mr&#x000f3;zek, GM and CDB were involved directly or indirectly in the care of patients and/or sample procurement.</p></fn><fn id="FN5"><p id="P35">Supplementary Information is available at Leukemia&#x02019;s website (<ext-link ext-link-type="uri" xlink:href="http://www.nature.com/leu">http://www.nature.com/leu</ext-link>)</p></fn></fn-group><ack id="S17"><title>ACKNOWLEDGEMENTS</title><p id="P36">The Cancer and Leukemia Group B institutions, and their principal investigators participating in this study are provided in the <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>. We thank Donna Bucci and the CALGB/Alliance Leukemia Tissue Bank at The Ohio State University Comprehensive Cancer Center, Columbus, OH, for sample processing and storage services; Lisa J. Sterling and Chris Finks for data management; and The Ohio State University Comprehensive Cancer Center&#x02019;s Nucleic Acid and Microarray Shared Resources for technical support. This work was supported in part by the National Cancer Institute (grants CA101140, CA114725, CA140158, CA31946, CA33601, CA16058, CA77658, and CA129657), the Coleman Leukemia Research Foundation, the Pelotonia Fellowship Program (A.-K.E.), the Conquer Cancer Foundation (J.H.M.) and the Deutsche Krebshilfe&#x02013;Dr Mildred Scheel Cancer Foundation (H.B.).</p></ack><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><name><surname>Heerema</surname><given-names>NA</given-names></name><name><surname>Bloomfield</surname><given-names>CD</given-names></name></person-group><article-title>Cytogenetics in acute leukemia</article-title><source>Blood Rev</source><year>2004</year><volume>18</volume><fpage>115</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">15010150</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Paschka</surname><given-names>P</given-names></name><name><surname>Whitman</surname><given-names>SP</given-names></name><name><surname>Bloomfield</surname><given-names>CD</given-names></name></person-group><article-title>Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?</article-title><source>Blood</source><year>2007</year><volume>109</volume><fpage>431</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">16960150</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>A</given-names></name><name><surname>Marcucci</surname><given-names>G</given-names></name></person-group><article-title>Molecular prognostic factors in cytogenetically normal acute myeloid leukemia</article-title><source>Expert Rev Hematol</source><year>2012</year><volume>5</volume><fpage>547</fpage><lpage>558</lpage><pub-id pub-id-type="pmid">23146058</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitman</surname><given-names>SP</given-names></name><name><surname>Maharry</surname><given-names>K</given-names></name><name><surname>Radmacher</surname><given-names>MD</given-names></name><name><surname>Becker</surname><given-names>H</given-names></name><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><name><surname>Margeson</surname><given-names>D</given-names></name><etal/></person-group><article-title>FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study</article-title><source>Blood</source><year>2010</year><volume>116</volume><fpage>3622</fpage><lpage>3626</lpage><pub-id pub-id-type="pmid">20656931</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>H</given-names></name><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Maharry</surname><given-names>K</given-names></name><name><surname>Radmacher</surname><given-names>MD</given-names></name><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><name><surname>Margeson</surname><given-names>D</given-names></name><etal/></person-group><article-title>Favorable prognostic impact of <italic>NPM1</italic> mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><fpage>596</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">20026798</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>H</given-names></name><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Maharry</surname><given-names>K</given-names></name><name><surname>Radmacher</surname><given-names>MD</given-names></name><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><name><surname>Margeson</surname><given-names>D</given-names></name><etal/></person-group><article-title>Mutations of the Wilms tumor 1 gene (<italic>WT1</italic>) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study</article-title><source>Blood</source><year>2010</year><volume>116</volume><fpage>788</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">20442368</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Maharry</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>Y-Z</given-names></name><name><surname>Radmacher</surname><given-names>MD</given-names></name><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><name><surname>Margeson</surname><given-names>D</given-names></name><etal/></person-group><article-title>IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><fpage>2348</fpage><lpage>2355</lpage><pub-id pub-id-type="pmid">20368543</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metzeler</surname><given-names>KH</given-names></name><name><surname>Becker</surname><given-names>H</given-names></name><name><surname>Maharry</surname><given-names>K</given-names></name><name><surname>Radmacher</surname><given-names>MD</given-names></name><name><surname>Kohlschmidt</surname><given-names>J</given-names></name><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><etal/></person-group><article-title><italic>ASXL1</italic> mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category</article-title><source>Blood</source><year>2011</year><volume>118</volume><fpage>6920</fpage><lpage>6929</lpage><pub-id pub-id-type="pmid">22031865</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Metzeler</surname><given-names>KH</given-names></name><name><surname>Schwind</surname><given-names>S</given-names></name><name><surname>Becker</surname><given-names>H</given-names></name><name><surname>Maharry</surname><given-names>K</given-names></name><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><etal/></person-group><article-title>Age-related prognostic impact of different types of <italic>DNMT3A</italic> mutations in adults with primary cytogenetically normal acute myeloid leukemia</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>742</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">22291079</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwind</surname><given-names>S</given-names></name><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Maharry</surname><given-names>K</given-names></name><name><surname>Radmacher</surname><given-names>MD</given-names></name><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><name><surname>Holland</surname><given-names>KB</given-names></name><etal/></person-group><article-title>BAALC and ERG expression levels are associated with outcome and distinct gene- and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study</article-title><source>Blood</source><year>2010</year><volume>116</volume><fpage>5660</fpage><lpage>5669</lpage><pub-id pub-id-type="pmid">20841507</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heuser</surname><given-names>M</given-names></name><name><surname>Beutel</surname><given-names>G</given-names></name><name><surname>Krauter</surname><given-names>J</given-names></name><name><surname>D&#x000f6;hner</surname><given-names>K</given-names></name><name><surname>von Neuhoff</surname><given-names>N</given-names></name><name><surname>Schlegelberger</surname><given-names>B</given-names></name><etal/></person-group><article-title>High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics</article-title><source>Blood</source><year>2006</year><volume>108</volume><fpage>3898</fpage><lpage>3905</lpage><pub-id pub-id-type="pmid">16912223</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwind</surname><given-names>S</given-names></name><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Kohlschmidt</surname><given-names>J</given-names></name><name><surname>Radmacher</surname><given-names>MD</given-names></name><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><name><surname>Maharry</surname><given-names>K</given-names></name><etal/></person-group><article-title>Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia</article-title><source>Blood</source><year>2011</year><volume>118</volume><fpage>4188</fpage><lpage>4198</lpage><pub-id pub-id-type="pmid">21828125</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><name><surname>Radmacher</surname><given-names>MD</given-names></name><name><surname>Garzon</surname><given-names>R</given-names></name><name><surname>Bloomfield</surname><given-names>CD</given-names></name></person-group><article-title>The prognostic and functional role of microRNAs in acute myeloid leukemia</article-title><source>Blood</source><year>2011</year><volume>117</volume><fpage>1121</fpage><lpage>1129</lpage><pub-id pub-id-type="pmid">21045193</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwind</surname><given-names>S</given-names></name><name><surname>Maharry</surname><given-names>K</given-names></name><name><surname>Radmacher</surname><given-names>MD</given-names></name><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><name><surname>Holland</surname><given-names>KB</given-names></name><name><surname>Margeson</surname><given-names>D</given-names></name><etal/></person-group><article-title>Prognostic significance of expression of a single microRNA, <italic>miR-181a</italic>, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><fpage>5257</fpage><lpage>5264</lpage><pub-id pub-id-type="pmid">21079133</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Maharry</surname><given-names>KS</given-names></name><name><surname>Metzeler</surname><given-names>KH</given-names></name><name><surname>Volinia</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Y-Z</given-names></name><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><etal/></person-group><article-title>Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: <italic>miR-155</italic> upregulation independently identifies high-risk patients</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>2086</fpage><lpage>2093</lpage><pub-id pub-id-type="pmid">23650424</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisfeld</surname><given-names>AK</given-names></name><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Maharry</surname><given-names>K</given-names></name><name><surname>Schwind</surname><given-names>S</given-names></name><name><surname>Radmacher</surname><given-names>MD</given-names></name><name><surname>Nicolet</surname><given-names>D</given-names></name><etal/></person-group><article-title><italic>miR-3151</italic> interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia</article-title><source>Blood</source><year>2012</year><volume>120</volume><fpage>249</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">22529287</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Yan</surname><given-names>P</given-names></name><name><surname>Maharry</surname><given-names>K</given-names></name><name><surname>Frankhouser</surname><given-names>D</given-names></name><name><surname>Nicolet</surname><given-names>D</given-names></name><name><surname>Metzeler</surname><given-names>KH</given-names></name><etal/></person-group><article-title>Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score</article-title><source>J Clin Oncol</source><year>2014</year><volume>32</volume><fpage>548</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">24378410</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>P</given-names></name><name><surname>Frankhouser</surname><given-names>D</given-names></name><name><surname>Murphy</surname><given-names>M</given-names></name><name><surname>Tam</surname><given-names>HH</given-names></name><name><surname>Rodriguez</surname><given-names>B</given-names></name><name><surname>Curfman</surname><given-names>J</given-names></name><etal/></person-group><article-title>Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia</article-title><source>Blood</source><year>2012</year><volume>120</volume><fpage>2466</fpage><lpage>2474</lpage><pub-id pub-id-type="pmid">22786882</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renneville</surname><given-names>A</given-names></name><name><surname>Boissel</surname><given-names>N</given-names></name><name><surname>Nibourel</surname><given-names>O</given-names></name><name><surname>Berthon</surname><given-names>C</given-names></name><name><surname>Helevaut</surname><given-names>N</given-names></name><name><surname>Gardin</surname><given-names>C</given-names></name><etal/></person-group><article-title>Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association</article-title><source>Leukemia</source><year>2012</year><volume>26</volume><fpage>1247</fpage><lpage>1254</lpage><pub-id pub-id-type="pmid">22289988</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hervouet</surname><given-names>E</given-names></name><name><surname>Vallette</surname><given-names>FM</given-names></name><name><surname>Cartron</surname><given-names>PF</given-names></name></person-group><article-title>Dnmt3/transcription factor interactions as crucial players in targeted DNA methylation</article-title><source>Epigenetics</source><year>2009</year><volume>4</volume><fpage>487</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">19786833</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trowbridge</surname><given-names>JJ</given-names></name><name><surname>Sinha</surname><given-names>AU</given-names></name><name><surname>Zhu</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Armstrong</surname><given-names>SA</given-names></name><name><surname>Orkin</surname><given-names>SH</given-names></name></person-group><article-title>Haploinsufficiency of <italic>Dnmt1</italic> impairs leukemia stem cell function through derepression of bivalent chromatin domains</article-title><source>Genes Dev</source><year>2012</year><volume>26</volume><fpage>344</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">22345515</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>KK</given-names></name><name><surname>Luo</surname><given-names>LF</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>SJ</given-names></name></person-group><article-title>DNA methyltransferases in hematologic malignancies</article-title><source>Semin Hematol</source><year>2013</year><volume>50</volume><fpage>48</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">23507483</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Walsh</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>DD</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Mao</surname><given-names>L</given-names></name></person-group><article-title>Expression of &#x00394;<italic>DNMT3B</italic> variants and its association with promoter methylation of p16 and <italic>RASSF1A</italic> in primary non-small cell lung cancer</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>8361</fpage><lpage>8366</lpage><pub-id pub-id-type="pmid">16951144</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hlady</surname><given-names>RA</given-names></name><name><surname>Novakova</surname><given-names>S</given-names></name><name><surname>Opavska</surname><given-names>J</given-names></name><name><surname>Klinkebiel</surname><given-names>D</given-names></name><name><surname>Peters</surname><given-names>SL</given-names></name><name><surname>Bies</surname><given-names>J</given-names></name><etal/></person-group><article-title>Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis</article-title><source>J Clin Invest</source><year>2012</year><volume>122</volume><fpage>163</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">22133874</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><collab>Cancer Genome Atlas Research Network</collab><article-title>Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia</article-title><source>New Engl J Med</source><year>2013</year><volume>368</volume><fpage>2059</fpage><lpage>2074</lpage><pub-id pub-id-type="pmid">23634996</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayette</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>X</given-names></name><name><surname>Jallades</surname><given-names>L</given-names></name><name><surname>Chabane</surname><given-names>K</given-names></name><name><surname>Charlot</surname><given-names>C</given-names></name><name><surname>Tigaud</surname><given-names>I</given-names></name><etal/></person-group><article-title>High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e51527</fpage><pub-id pub-id-type="pmid">23251566</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blum</surname><given-names>W</given-names></name><name><surname>Garzon</surname><given-names>R</given-names></name><name><surname>Klisovic</surname><given-names>RB</given-names></name><name><surname>Schwind</surname><given-names>S</given-names></name><name><surname>Walker</surname><given-names>A</given-names></name><name><surname>Geyer</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinical response and <italic>miR-29b</italic> predictive significance in older AML patients treated with a 10-day schedule of decitabine</article-title><source>Proc Natl Acad Sci U S A</source><year>2010</year><volume>107</volume><fpage>7473</fpage><lpage>7478</lpage><pub-id pub-id-type="pmid">20368434</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer</surname><given-names>RJ</given-names></name><name><surname>Davis</surname><given-names>RB</given-names></name><name><surname>Schiffer</surname><given-names>CA</given-names></name><name><surname>Berg</surname><given-names>DT</given-names></name><name><surname>Powell</surname><given-names>BL</given-names></name><name><surname>Schulman</surname><given-names>P</given-names></name><etal/></person-group><article-title>Intensive postremission chemotherapy in adults with acute myeloid leukemia</article-title><source>N Engl J Med</source><year>1994</year><volume>331</volume><fpage>896</fpage><lpage>903</lpage><pub-id pub-id-type="pmid">8078551</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>RM</given-names></name><name><surname>Berg</surname><given-names>DT</given-names></name><name><surname>George</surname><given-names>SL</given-names></name><name><surname>Dodge</surname><given-names>RK</given-names></name><name><surname>Paciucci</surname><given-names>PA</given-names></name><name><surname>Schulman</surname><given-names>P</given-names></name><etal/></person-group><article-title>Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia</article-title><source>N Engl J Med</source><year>1995</year><volume>332</volume><fpage>1671</fpage><lpage>1677</lpage><pub-id pub-id-type="pmid">7760868</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>EJ</given-names></name><name><surname>George</surname><given-names>SL</given-names></name><name><surname>Caligiuri</surname><given-names>M</given-names></name><name><surname>Szatrowski</surname><given-names>TP</given-names></name><name><surname>Powell</surname><given-names>BL</given-names></name><name><surname>Lemke</surname><given-names>S</given-names></name><etal/></person-group><article-title>Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of Cancer and Leukemia Group B study 9420</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>2831</fpage><lpage>2839</lpage><pub-id pub-id-type="pmid">10561359</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baer</surname><given-names>MR</given-names></name><name><surname>George</surname><given-names>SL</given-names></name><name><surname>Sanford</surname><given-names>BL</given-names></name><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><name><surname>Kolitz</surname><given-names>JE</given-names></name><name><surname>Moore</surname><given-names>JO</given-names></name><etal/></person-group><article-title>Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B study 9720</article-title><source>Leukemia</source><year>2011</year><volume>25</volume><fpage>800</fpage><lpage>807</lpage><pub-id pub-id-type="pmid">21321569</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Moser</surname><given-names>B</given-names></name><name><surname>Blum</surname><given-names>W</given-names></name><name><surname>Stock</surname><given-names>W</given-names></name><name><surname>Wetzler</surname><given-names>M</given-names></name><name><surname>Kolitz</surname><given-names>JE</given-names></name><etal/></person-group><article-title>A phase III randomized trial of intensive induction and consolidation chemotherapy &#x000b1; oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients &#x0003e;60 years old</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><issue>suppl</issue><fpage>360s</fpage><comment>(abstract 7012).</comment></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><name><surname>Carroll</surname><given-names>AJ</given-names></name><name><surname>Maharry</surname><given-names>K</given-names></name><name><surname>Rao</surname><given-names>KW</given-names></name><name><surname>Patil</surname><given-names>SR</given-names></name><name><surname>Pettenati</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience</article-title><source>Int J Oncol</source><year>2008</year><volume>33</volume><fpage>239</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">18636143</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Payton</surname><given-names>JE</given-names></name><name><surname>Grieselhuber</surname><given-names>NR</given-names></name><name><surname>Chang</surname><given-names>LW</given-names></name><name><surname>Murakami</surname><given-names>M</given-names></name><name><surname>Geiss</surname><given-names>GK</given-names></name><name><surname>Link</surname><given-names>DC</given-names></name><etal/></person-group><article-title>High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples</article-title><source>J Clin Invest</source><year>2009</year><volume>119</volume><fpage>1714</fpage><lpage>1726</lpage><pub-id pub-id-type="pmid">19451695</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitman</surname><given-names>SP</given-names></name><name><surname>Archer</surname><given-names>KJ</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Baldus</surname><given-names>C</given-names></name><name><surname>Becknell</surname><given-names>B</given-names></name><name><surname>Carlson</surname><given-names>BD</given-names></name><etal/></person-group><article-title>Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>7233</fpage><lpage>7239</lpage><pub-id pub-id-type="pmid">11585760</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiede</surname><given-names>C</given-names></name><name><surname>Steudel</surname><given-names>C</given-names></name><name><surname>Mohr</surname><given-names>B</given-names></name><name><surname>Schaich</surname><given-names>M</given-names></name><name><surname>Sch&#x000e4;kel</surname><given-names>U</given-names></name><name><surname>Platzbecker</surname><given-names>U</given-names></name><etal/></person-group><article-title>Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis</article-title><source>Blood</source><year>2002</year><volume>99</volume><fpage>4326</fpage><lpage>4335</lpage><pub-id pub-id-type="pmid">12036858</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Kiyoi</surname><given-names>H</given-names></name><name><surname>Nakano</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>R</given-names></name><name><surname>Kodera</surname><given-names>Y</given-names></name><name><surname>Miyawaki</surname><given-names>S</given-names></name><etal/></person-group><article-title>Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</article-title><source>Blood</source><year>2001</year><volume>97</volume><fpage>2434</fpage><lpage>2439</lpage><pub-id pub-id-type="pmid">11290608</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitman</surname><given-names>SP</given-names></name><name><surname>Ruppert</surname><given-names>AS</given-names></name><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><name><surname>Paschka</surname><given-names>P</given-names></name><name><surname>Langer</surname><given-names>C</given-names></name><etal/></person-group><article-title>Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study</article-title><source>Blood</source><year>2007</year><volume>109</volume><fpage>5164</fpage><lpage>5167</lpage><pub-id pub-id-type="pmid">17341662</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Maharry</surname><given-names>K</given-names></name><name><surname>Radmacher</surname><given-names>MD</given-names></name><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><name><surname>Vukosavljevic</surname><given-names>T</given-names></name><name><surname>Paschka</surname><given-names>P</given-names></name><etal/></person-group><article-title>Prognostic significance of gene and microRNA expression signatures associated with, <italic>CEBPA</italic> mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B study</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>5078</fpage><lpage>5087</lpage><pub-id pub-id-type="pmid">18809607</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paschka</surname><given-names>P</given-names></name><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Ruppert</surname><given-names>AS</given-names></name><name><surname>Whitman</surname><given-names>SP</given-names></name><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><name><surname>Maharry</surname><given-names>K</given-names></name><etal/></person-group><article-title>Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>4595</fpage><lpage>4602</lpage><pub-id pub-id-type="pmid">18559874</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metzeler</surname><given-names>KH</given-names></name><name><surname>Maharry</surname><given-names>K</given-names></name><name><surname>Radmacher</surname><given-names>MD</given-names></name><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><name><surname>Margeson</surname><given-names>D</given-names></name><name><surname>Becker</surname><given-names>H</given-names></name><etal/></person-group><article-title>TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>1373</fpage><lpage>1381</lpage><pub-id pub-id-type="pmid">21343549</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendler</surname><given-names>JH</given-names></name><name><surname>Maharry</surname><given-names>K</given-names></name><name><surname>Radmacher</surname><given-names>MD</given-names></name><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><name><surname>Becker</surname><given-names>H</given-names></name><name><surname>Metzeler</surname><given-names>KH</given-names></name><etal/></person-group><article-title>RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>3109</fpage><lpage>3118</lpage><pub-id pub-id-type="pmid">22753902</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Radmacher</surname><given-names>MD</given-names></name><name><surname>Maharry</surname><given-names>K</given-names></name><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><name><surname>Ruppert</surname><given-names>AS</given-names></name><name><surname>Paschka</surname><given-names>P</given-names></name><etal/></person-group><article-title>MicroRNA expression in cytogenetically normal acute myeloid leukemia</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>1919</fpage><lpage>1928</lpage><pub-id pub-id-type="pmid">18450603</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metzeler</surname><given-names>KH</given-names></name><name><surname>Hummel</surname><given-names>M</given-names></name><name><surname>Bloomfield</surname><given-names>CD</given-names></name><name><surname>Spiekermann</surname><given-names>K</given-names></name><name><surname>Braess</surname><given-names>J</given-names></name><name><surname>Sauerland</surname><given-names>MC</given-names></name><etal/></person-group><article-title>An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia</article-title><source>Blood</source><year>2008</year><volume>112</volume><fpage>4193</fpage><lpage>4201</lpage><pub-id pub-id-type="pmid">18716133</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang da</surname><given-names>W</given-names></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Lempicki</surname><given-names>RA</given-names></name></person-group><article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title><source>Nat Protoc</source><year>2009</year><volume>4</volume><fpage>44</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">19131956</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Vittinghoff</surname><given-names>E</given-names></name><name><surname>Glidden</surname><given-names>DV</given-names></name><name><surname>Shiboski</surname><given-names>SC</given-names></name><name><surname>McCulloch</surname><given-names>CE</given-names></name></person-group><source>Regression Methods in Biostatistics: Linear, Logistic, Survival and Repeated Measures Models</source><year>2005</year><publisher-loc>New York, NY, USA</publisher-loc><publisher-name>Springer</publisher-name></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x000f6;hner</surname><given-names>H</given-names></name><name><surname>Estey</surname><given-names>EH</given-names></name><name><surname>Amadori</surname><given-names>S</given-names></name><name><surname>Appelbaum</surname><given-names>FR</given-names></name><name><surname>B&#x000fc;chner</surname><given-names>T</given-names></name><name><surname>Burnett</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet</article-title><source>Blood</source><year>2010</year><volume>115</volume><fpage>453</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">19880497</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Lan</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>MiR-133b is down-regulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes apoptosis</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e83571</fpage><pub-id pub-id-type="pmid">24391788</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>F-T</given-names></name><name><surname>Qian</surname><given-names>F</given-names></name><name><surname>Fang</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>K-Y</given-names></name><name><surname>Wang</surname><given-names>W-T</given-names></name><name><surname>Chen</surname><given-names>Y-Q</given-names></name></person-group><article-title>miR-133b, a muscle-specific microRNA, is a novel prognostic marker that participates in the progression of human colorectal cancer via regulation of CXCR4 expression</article-title><source>Mol Cancer</source><year>2013</year><volume>12</volume><fpage>164</fpage><pub-id pub-id-type="pmid">24330809</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sturrock</surname><given-names>A</given-names></name><name><surname>Mir-Kasimov</surname><given-names>M</given-names></name><name><surname>Baker</surname><given-names>J</given-names></name><name><surname>Rowley</surname><given-names>J</given-names></name><name><surname>Paine</surname><given-names>R</given-names><suffix>3rd</suffix></name></person-group><article-title>Key role of microRNA in the regulation of granulocyte macrophage colony-stimulating factor expression in murine alveolar epithelial cells during oxidative stress</article-title><source>J Biol Chem</source><year>2014</year><volume>289</volume><fpage>4095</fpage><lpage>4105</lpage><pub-id pub-id-type="pmid">24371146</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duursma</surname><given-names>AM</given-names></name><name><surname>Kedde</surname><given-names>M</given-names></name><name><surname>Schrier</surname><given-names>M</given-names></name><name><surname>le Sage</surname><given-names>C</given-names></name><name><surname>Agami</surname><given-names>R</given-names></name></person-group><article-title>miR-148 targets human DNMT3b protein coding region</article-title><source>RNA</source><year>2008</year><volume>14</volume><fpage>872</fpage><lpage>877</lpage><pub-id pub-id-type="pmid">18367714</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>A</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Zuo</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Yao</surname><given-names>L</given-names></name><etal/></person-group><article-title>MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer</article-title><source>Med Oncol</source><year>2012</year><volume>29</volume><fpage>2701</fpage><lpage>2709</lpage><pub-id pub-id-type="pmid">22167392</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>SH</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Kota</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Costinean</surname><given-names>S</given-names></name><name><surname>Kutay</surname><given-names>H</given-names></name><etal/></person-group><article-title>Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver</article-title><source>J Clin Invest</source><year>2012</year><volume>122</volume><fpage>2871</fpage><lpage>2883</lpage><pub-id pub-id-type="pmid">22820288</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000f6;berle</surname><given-names>V</given-names></name><name><surname>Kronenberger</surname><given-names>B</given-names></name><name><surname>Pleli</surname><given-names>T</given-names></name><name><surname>Trojan</surname><given-names>J</given-names></name><name><surname>Imelmann</surname><given-names>E</given-names></name><name><surname>Peveling-Oberhag</surname><given-names>J</given-names></name><etal/></person-group><article-title>Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma</article-title><source>Eur J Cancer</source><year>2013</year><volume>49</volume><fpage>3442</fpage><lpage>3449</lpage><pub-id pub-id-type="pmid">23810247</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>MiR-122 modulates type I interferon expression through blocking suppressor of cytokine signaling 1</article-title><source>Int J Biochem Cell Biol</source><year>2013</year><volume>45</volume><fpage>858</fpage><lpage>865</lpage><pub-id pub-id-type="pmid">23348614</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Zha</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Jia</surname><given-names>D</given-names></name><etal/></person-group><article-title>MicroRNA-409 suppresses tumour cell invasion and metastasis by directly targeting radixin in gastric cancers</article-title><source>Oncogene</source><year>2012</year><volume>31</volume><fpage>4509</fpage><lpage>4516</lpage><pub-id pub-id-type="pmid">22179828</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mr&#x000f3;zek</surname><given-names>K</given-names></name><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Nicolet</surname><given-names>D</given-names></name><name><surname>Maharry</surname><given-names>KS</given-names></name><name><surname>Becker</surname><given-names>H</given-names></name><name><surname>Whitman</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>4515</fpage><lpage>4523</lpage><pub-id pub-id-type="pmid">22987078</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaidzik</surname><given-names>VI</given-names></name><name><surname>Schlenk</surname><given-names>RF</given-names></name><name><surname>Paschka</surname><given-names>P</given-names></name><name><surname>St&#x000f6;lzle</surname><given-names>A</given-names></name><name><surname>Sp&#x000e4;th</surname><given-names>D</given-names></name><name><surname>Kuendgen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)</article-title><source>Blood</source><year>2013</year><volume>121</volume><fpage>4769</fpage><lpage>4777</lpage><pub-id pub-id-type="pmid">23632886</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagemann</surname><given-names>S</given-names></name><name><surname>Kuck</surname><given-names>D</given-names></name><name><surname>Stresemann</surname><given-names>C</given-names></name><name><surname>Prinz</surname><given-names>F</given-names></name><name><surname>Brueckner</surname><given-names>B</given-names></name><name><surname>Mund</surname><given-names>C</given-names></name><etal/></person-group><article-title>Antiproliferative effects of DNA methyltransferase 3B depletion are not associated with DNA demethylation</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e36125</fpage><pub-id pub-id-type="pmid">22563479</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russler-Germain</surname><given-names>DA</given-names></name><name><surname>Spencer</surname><given-names>DH</given-names></name><name><surname>Young</surname><given-names>MA</given-names></name><name><surname>Lamprecht</surname><given-names>TL</given-names></name><name><surname>Miller</surname><given-names>CA</given-names></name><name><surname>Fulton</surname><given-names>R</given-names></name><etal/></person-group><article-title>The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers</article-title><source>Cancer Cell</source><year>2014</year><volume>25</volume><fpage>442</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">24656771</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p id="P37">Clinical outcome of CN-AML patients with high and low <italic>DNMT3B</italic> expression. Kaplan-Meier survival curves for (<bold>a</bold>) disease-free survival and (<bold>b</bold>) overall survival. <italic>P</italic>-values presented are from the log rank test.</p></caption><graphic xlink:href="nihms624934f1"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p id="P38">Clinical outcome of CN-AML patients with high and low <italic>DNMT3B</italic> expression classified into European LeukemiaNet (ELN) Genetic Groups. Kaplan-Meier survival curves for (<bold>a</bold>) disease-free survival and (<bold>b</bold>) overall survival of patients in the ELN modified Favorable Genetic Group; (<bold>c</bold>) disease-free survival and (<bold>d</bold>) overall survival of patients in the ELN Intermediate-I Genetic Group. <italic>P</italic>-values presented are from the log rank test.</p></caption><graphic xlink:href="nihms624934f2a"/><graphic xlink:href="nihms624934f2b"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><p id="P39">Comparison of clinical and molecular characteristics of patients with cytogenetically normal acute myeloid leukemia with high versus low <italic>DNMT3B</italic> expression</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1">High DNMT3B<break/>(n=105)</th><th align="center" rowspan="1" colspan="1">Low DNMT3B<break/>(n=105)</th><th align="center" valign="top" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>Age, years</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Median</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Range</td><td align="center" rowspan="1" colspan="1">60&#x02013;83</td><td align="center" rowspan="1" colspan="1">60&#x02013;81</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Sex, n (%)</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Male</td><td align="center" rowspan="1" colspan="1">58 (55)</td><td align="center" rowspan="1" colspan="1">53 (50)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Female</td><td align="center" rowspan="1" colspan="1">47 (45)</td><td align="center" rowspan="1" colspan="1">52 (50)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Race, n (%)</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;White</td><td align="center" rowspan="1" colspan="1">96 (92)</td><td align="center" rowspan="1" colspan="1">92 (89)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Nonwhite</td><td align="center" rowspan="1" colspan="1">8 (8)</td><td align="center" rowspan="1" colspan="1">11 (11)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Hemoglobin, g/dl</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Median</td><td align="center" rowspan="1" colspan="1">9.4</td><td align="center" rowspan="1" colspan="1">9.3</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Range</td><td align="center" rowspan="1" colspan="1">6.5&#x02013;12.4</td><td align="center" rowspan="1" colspan="1">5.4&#x02013;15.0</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Platelet count, &#x000d7; 10<sup>9</sup>/l</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Median</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Range</td><td align="center" rowspan="1" colspan="1">4&#x02013;850</td><td align="center" rowspan="1" colspan="1">11&#x02013;510</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>WBC, &#x000d7; 10<sup>9</sup>/l</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Median</td><td align="center" rowspan="1" colspan="1">43.7</td><td align="center" rowspan="1" colspan="1">21.8</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Range</td><td align="center" rowspan="1" colspan="1">1.0&#x02013;450.0</td><td align="center" rowspan="1" colspan="1">0.8&#x02013;249.3</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Blood blasts, %</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Median</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Range</td><td align="center" rowspan="1" colspan="1">0&#x02013;99</td><td align="center" rowspan="1" colspan="1">0&#x02013;97</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Bone marrow blasts, %</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Median</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Range</td><td align="center" rowspan="1" colspan="1">21&#x02013;97</td><td align="center" rowspan="1" colspan="1">4&#x02013;97</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Extramedullary involvement, n (%)</italic></td><td align="center" rowspan="1" colspan="1">27 (27)</td><td align="center" rowspan="1" colspan="1">24 (23)</td><td align="center" rowspan="1" colspan="1">0.63</td></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>NPM1, n (%)</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Mutated</td><td align="center" rowspan="1" colspan="1">67 (66)</td><td align="center" rowspan="1" colspan="1">60 (59)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Wild-type</td><td align="center" rowspan="1" colspan="1">34 (34)</td><td align="center" rowspan="1" colspan="1">42 (41)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>FLT3-ITD, n (%)</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Present</td><td align="center" rowspan="1" colspan="1">54 (53)</td><td align="center" rowspan="1" colspan="1">21 (21)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Absent</td><td align="center" rowspan="1" colspan="1">48 (47)</td><td align="center" rowspan="1" colspan="1">81 (79)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>CEBPA, n (%)</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.83<xref ref-type="table-fn" rid="TFN2">a</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Mutated</td><td align="center" rowspan="1" colspan="1">13 (13)</td><td align="center" rowspan="1" colspan="1">12 (12)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Single mutated</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Double mutated</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Wild-type</td><td align="center" rowspan="1" colspan="1">88 (87)</td><td align="center" rowspan="1" colspan="1">90 (88)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>ELN Genetic Group</italic><xref ref-type="table-fn" rid="TFN3">b</xref>, <italic>n (%)</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Modified Favorable</td><td align="center" rowspan="1" colspan="1">38 (38)</td><td align="center" rowspan="1" colspan="1">56 (55)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Intermediate-I</td><td align="center" rowspan="1" colspan="1">63 (62)</td><td align="center" rowspan="1" colspan="1">45 (45)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>FLT3-TKD, n (%)</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Present</td><td align="center" rowspan="1" colspan="1">12 (12)</td><td align="center" rowspan="1" colspan="1">11 (11)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Absent</td><td align="center" rowspan="1" colspan="1">89 (88)</td><td align="center" rowspan="1" colspan="1">91 (89)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>WT1, n (%)</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.41</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Mutated</td><td align="center" rowspan="1" colspan="1">8 (8)</td><td align="center" rowspan="1" colspan="1">5 (5)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Wild-type</td><td align="center" rowspan="1" colspan="1">93 (92)</td><td align="center" rowspan="1" colspan="1">97 (95)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>TET2, n (%)</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Mutated</td><td align="center" rowspan="1" colspan="1">32 (32)</td><td align="center" rowspan="1" colspan="1">31 (32)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Wild-type</td><td align="center" rowspan="1" colspan="1">68 (68)</td><td align="center" rowspan="1" colspan="1">67 (68)</td></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>MLL-PTD, n (%)</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Present</td><td align="center" rowspan="1" colspan="1">5 (6)</td><td align="center" rowspan="1" colspan="1">5 (6)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Absent</td><td align="center" rowspan="1" colspan="1">74 (94)</td><td align="center" rowspan="1" colspan="1">81 (94)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>IDH1, n (%)</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Mutated</td><td align="center" rowspan="1" colspan="1">14 (14)</td><td align="center" rowspan="1" colspan="1">8 (8)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Wild-type</td><td align="center" rowspan="1" colspan="1">86 (86)</td><td align="center" rowspan="1" colspan="1">94 (92)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>IDH2, n (%)</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Mutated</td><td align="center" rowspan="1" colspan="1">18 (18)</td><td align="center" rowspan="1" colspan="1">31 (30)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;R140</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">0.005<xref ref-type="table-fn" rid="TFN4">c</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;R172</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0.13<xref ref-type="table-fn" rid="TFN5">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Wild-type</td><td align="center" rowspan="1" colspan="1">82 (82)</td><td align="center" rowspan="1" colspan="1">71 (70)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>RUNX1, n (%)</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Mutated</td><td align="center" rowspan="1" colspan="1">17 (18)</td><td align="center" rowspan="1" colspan="1">11 (12)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Wild-type</td><td align="center" rowspan="1" colspan="1">79 (82)</td><td align="center" rowspan="1" colspan="1">81 (88)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>ASXL1, n (%)</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.69</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Mutated</td><td align="center" rowspan="1" colspan="1">13 (13)</td><td align="center" rowspan="1" colspan="1">15 (15)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Wild-type</td><td align="center" rowspan="1" colspan="1">87 (87)</td><td align="center" rowspan="1" colspan="1">84 (85)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>DNMT3A</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.65</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Mutated</td><td align="center" rowspan="1" colspan="1">35 (35)</td><td align="center" rowspan="1" colspan="1">31 (32)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;R882</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">1.00<xref ref-type="table-fn" rid="TFN6">e</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Non-R882</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">0.40<xref ref-type="table-fn" rid="TFN7">f</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Wild-type</td><td align="center" rowspan="1" colspan="1">64 (65)</td><td align="center" rowspan="1" colspan="1">66 (68)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>ERG expression group</italic>,<xref ref-type="table-fn" rid="TFN8">g</xref>,<xref ref-type="table-fn" rid="TFN9">h</xref>
<italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;High</td><td align="center" rowspan="1" colspan="1">65 (62)</td><td align="center" rowspan="1" colspan="1">40 (38)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Low</td><td align="center" rowspan="1" colspan="1">40 (38)</td><td align="center" rowspan="1" colspan="1">65 (62)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>BAALC expression group</italic>,<xref ref-type="table-fn" rid="TFN8">g</xref>,<xref ref-type="table-fn" rid="TFN9">h</xref>
<italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;High</td><td align="center" rowspan="1" colspan="1">64 (61)</td><td align="center" rowspan="1" colspan="1">41 (39)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Low</td><td align="center" rowspan="1" colspan="1">41 (39)</td><td align="center" rowspan="1" colspan="1">64 (61)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>miR-155 expression group</italic>,<xref ref-type="table-fn" rid="TFN8">g</xref>,<xref ref-type="table-fn" rid="TFN9">h</xref>
<italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;High</td><td align="center" rowspan="1" colspan="1">63 (60)</td><td align="center" rowspan="1" colspan="1">42 (40)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Low</td><td align="center" rowspan="1" colspan="1">42 (40)</td><td align="center" rowspan="1" colspan="1">63 (60)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>miR-3151 expression group</italic>,<xref ref-type="table-fn" rid="TFN8">g</xref>,<xref ref-type="table-fn" rid="TFN10">i</xref>
<italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.76</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;High</td><td align="center" rowspan="1" colspan="1">42 (49)</td><td align="center" rowspan="1" colspan="1">39 (46)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Low</td><td align="center" rowspan="1" colspan="1">43 (51)</td><td align="center" rowspan="1" colspan="1">46 (54)</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN1" fn-type="abbr"><p id="P40">Abbreviations: ELN, European LeukemiaNet; <italic>FLT3</italic>-ITD, internal tandem duplication of the <italic>FLT3</italic> gene; <italic>FLT3</italic>-TKD, tyrosine kinase domain mutation in the <italic>FLT3</italic> gene; <italic>MLL</italic>-PTD, partial tandem duplication of the <italic>MLL</italic> gene; n, number; WBC, white blood count.</p></fn><fn id="TFN2"><label>a</label><p id="P41">The <italic>P</italic>-value pertains to a comparison of frequencies of <italic>CEBPA</italic> mutations (single and double combined) versus <italic>CEBPA</italic> wild-type between high and low <italic>DNMT3B</italic> expressers.</p></fn><fn id="TFN3"><label>b</label><p id="P42">The ELN modified Favorable Genetic Group is defined as CN-AML patients with mutated <italic>CEBPA</italic> and/or mutated <italic>NPM1</italic> without <italic>FLT3</italic>-ITD. All remaining CN-AML patients (i.e., those with wild-type <italic>CEBPA</italic> and wild-type <italic>NPM1</italic> with or without <italic>FLT3</italic>-ITD, or mutated <italic>NPM1</italic> with <italic>FLT3</italic>-ITD) belong to the ELN Intermediate-I Genetic Group.<sup><xref rid="R47" ref-type="bibr">47</xref></sup></p></fn><fn id="TFN4"><label>c</label><p id="P43">The <italic>P</italic>-value pertains to a comparison of frequencies of <italic>IDH2</italic>-R140 mutations versus <italic>IDH2</italic> wild-type between high and low <italic>DNMT3B</italic> expressers.</p></fn><fn id="TFN5"><label>d</label><p id="P44">The <italic>P</italic>-value pertains to a comparison of frequencies of <italic>IDH2</italic>-R172 mutations versus <italic>IDH2</italic> wild-type between high and low <italic>DNMT3B</italic> expressers.</p></fn><fn id="TFN6"><label>e</label><p id="P45">The P-value pertains to a comparison of frequencies of DNMT3A-R882 mutations versus DNMT3A wild-type between high and low DNMT3B expressers.</p></fn><fn id="TFN7"><label>f</label><p id="P46">The <italic>P</italic>-value pertains to a comparison of frequencies of <italic>DNMT3A</italic> non-R882 mutations versus <italic>DNMT3A</italic> wild-type between high and low <italic>DNMT3B</italic> expressers.</p></fn><fn id="TFN8"><label>g</label><p id="P47">The median expression value was used as a cut point.</p></fn><fn id="TFN9"><label>h</label><p id="P48">Data was assessed by the NanoString nCounter assay.</p></fn><fn id="TFN10"><label>i</label><p id="P49">Data was assessed by real-time RT-PCR.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float" orientation="portrait"><label>Table 2</label><caption><p id="P50">Outcomes of patients with cytogenetically normal acute myeloid leukemia according to <italic>DNMT3B</italic> expression status</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Endpoint</th><th align="center" valign="top" rowspan="1" colspan="1">High DNMT3B<break/>(I)</th><th align="center" valign="top" rowspan="1" colspan="1">Low DNMT3B<break/>(II)</th><th align="center" valign="top" rowspan="1" colspan="1">P<xref ref-type="table-fn" rid="TFN12">a</xref></th><th align="center" rowspan="1" colspan="1">OR/HR<break/>(95% CI)<break/>I vs II</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">All patients</td><td align="center" rowspan="1" colspan="1">n=105</td><td align="center" rowspan="1" colspan="1">n=105</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;<italic>Complete remission, n</italic> (%)</td><td align="center" rowspan="1" colspan="1">61 (58)</td><td align="center" rowspan="1" colspan="1">82 (78)</td><td align="center" rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">0.39 (0.21&#x02013;0.71)</td></tr><tr><td align="center" colspan="5" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;<italic>Disease-free survival</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">1.55 (1.09&#x02013;2.20)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Median, years</td><td align="center" rowspan="1" colspan="1">0.6</td><td align="center" rowspan="1" colspan="1">1.1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;% Disease-free at 3 years (95% CI)</td><td align="center" rowspan="1" colspan="1">13 (6&#x02013;23)</td><td align="center" rowspan="1" colspan="1">22 (14&#x02013;31)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;% Disease-free at 5 years (95% CI)</td><td align="center" rowspan="1" colspan="1">11 (5&#x02013;21)</td><td align="center" rowspan="1" colspan="1">15 (8&#x02013;23)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;<italic>Overall survival</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">1.85 (1.38&#x02013;2.47)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Median, years</td><td align="center" rowspan="1" colspan="1">0.8</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;% Alive at 3 years (95% CI)</td><td align="center" rowspan="1" colspan="1">11 (6&#x02013;18)</td><td align="center" rowspan="1" colspan="1">29 (20&#x02013;37)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;% Alive at 5 years (95% CI)</td><td align="center" rowspan="1" colspan="1">8 (4&#x02013;14)</td><td align="center" rowspan="1" colspan="1">21 (14&#x02013;29)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Patients in the ELN modified Favorable Genetic Group<xref ref-type="table-fn" rid="TFN13">b</xref></td><td align="center" rowspan="1" colspan="1">n=38</td><td align="center" rowspan="1" colspan="1">n=56</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;<italic>Complete remission, n</italic> (%)</td><td align="center" rowspan="1" colspan="1">27 (71)</td><td align="center" rowspan="1" colspan="1">47 (84)</td><td align="center" rowspan="1" colspan="1">0.14</td><td align="center" rowspan="1" colspan="1">0.47 (0.17&#x02013;1.28)</td></tr><tr><td align="center" colspan="5" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;<italic>Disease-free survival</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.10</td><td align="center" rowspan="1" colspan="1">1.54 (0.92&#x02013;2.57)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Median, years</td><td align="center" rowspan="1" colspan="1">0.9</td><td align="center" rowspan="1" colspan="1">1.3</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;% Disease-free at 3 years (95% CI)</td><td align="center" rowspan="1" colspan="1">15 (5&#x02013;30)</td><td align="center" rowspan="1" colspan="1">30 (18&#x02013;43)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;% Disease-free at 5 years (95% CI)</td><td align="center" rowspan="1" colspan="1">11 (3&#x02013;26)</td><td align="center" rowspan="1" colspan="1">21 (11&#x02013;34)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;<italic>Overall survival</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">2.04 (1.29&#x02013;3.22)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Median, years</td><td align="center" rowspan="1" colspan="1">1.3</td><td align="center" rowspan="1" colspan="1">2.1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;% Alive at 3 years (95% CI)</td><td align="center" rowspan="1" colspan="1">18 (7&#x02013;31)</td><td align="center" rowspan="1" colspan="1">39 (27&#x02013;52)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;% Alive at 5 years (95% CI)</td><td align="center" rowspan="1" colspan="1">12 (4&#x02013;24)</td><td align="center" rowspan="1" colspan="1">30 (19&#x02013;43)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Patients in the ELN Intermediate-I Genetic Group<xref ref-type="table-fn" rid="TFN13">b</xref></td><td align="center" rowspan="1" colspan="1">n=63</td><td align="center" rowspan="1" colspan="1">n=45</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;<italic>Complete remission, n</italic>(%)</td><td align="center" rowspan="1" colspan="1">31 (49)</td><td align="center" rowspan="1" colspan="1">33 (73)</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">0.35 (0.15&#x02013;0.80)</td></tr><tr><td align="center" colspan="5" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;<italic>Disease-free survival</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.25</td><td align="center" rowspan="1" colspan="1">1.36 (0.81&#x02013;2.27)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Median, years</td><td align="center" rowspan="1" colspan="1">0.5</td><td align="center" rowspan="1" colspan="1">0.7</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;% Disease-free at 3 years (95% CI)</td><td align="center" rowspan="1" colspan="1">13 (4&#x02013;27)</td><td align="center" rowspan="1" colspan="1">9 (2&#x02013;22)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;% Disease-free at 5 years (95% CI)</td><td align="center" rowspan="1" colspan="1">13 (4&#x02013;27)</td><td align="center" rowspan="1" colspan="1">3 (0&#x02013;13)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;<italic>Overall survival</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">1.57 (1.06&#x02013;2.33)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Median, years</td><td align="center" rowspan="1" colspan="1">0.6</td><td align="center" rowspan="1" colspan="1">1.1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;% Alive at 3 years (95% CI)</td><td align="center" rowspan="1" colspan="1">8 (3&#x02013;16)</td><td align="center" rowspan="1" colspan="1">16 (7&#x02013;28)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;% Alive at 5 years (95% CI)</td><td align="center" rowspan="1" colspan="1">6 (2&#x02013;14)</td><td align="center" rowspan="1" colspan="1">9 (3&#x02013;19)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN11" fn-type="abbr"><p id="P51">Abbreviations: CI, confidence interval; ELN, European Leukemia Net; HR, hazard ratio; n, number; OR, odds ratio.</p></fn><fn id="TFN12"><label>a</label><p id="P52"><italic>P</italic>-values provided are generated by logistic regression and Cox proportional hazards models to compare outcome of patients for CR and survival endpoints (DFS, OS), respectively, using the Wald test.</p></fn><fn id="TFN13"><label>b</label><p id="P53">The ELN modified Favorable Genetic Group is defined as CN-AML patients with mutated <italic>CEBPA</italic> and/or mutated <italic>NPM1</italic> without <italic>FLT3</italic>-ITD. All remaining CN-AML patients (i.e., those with wild-type <italic>CEBPA</italic> and wild-type <italic>NPM1</italic> with or without <italic>FLT3</italic>-ITD, or mutated <italic>NPM1</italic> with <italic>FLT3</italic>-ITD) belong to the ELN Intermediate-I Genetic Group.<sup><xref rid="R47" ref-type="bibr">47</xref></sup></p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float" orientation="landscape"><label>Table 3</label><caption><p id="P54">Multivariable analyses of CN-AML patients according to DNMT3B expression status</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" valign="middle" colspan="1">Variable</th><th align="center" colspan="2" valign="top" rowspan="1">Complete remission</th><th align="center" colspan="2" valign="top" rowspan="1">Disease-free survival</th><th align="center" colspan="2" valign="top" rowspan="1">Overall survival</th></tr><tr><th align="center" colspan="6" valign="bottom" rowspan="1"><hr/></th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="top" rowspan="1" colspan="1">P</th><th align="center" valign="top" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="top" rowspan="1" colspan="1">P</th><th align="center" valign="top" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" valign="top" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">All patients</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="7" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>DNMT3B</italic> expression, high vs low</td><td align="center" rowspan="1" colspan="1">0.49 (0.25&#x02013;0.97)</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">1.47 (1.01&#x02013;2.13)</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">1.72 (1.24&#x02013;2.38)</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="center" colspan="7" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>BAALC</italic> expression, high vs low</td><td align="center" rowspan="1" colspan="1">0.21 (0.10&#x02013;0.43)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">1.79 (1.21&#x02013;2.65)</td><td align="center" rowspan="1" colspan="1">0.004</td><td align="center" rowspan="1" colspan="1">1.98 (1.39&#x02013;2.80)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" colspan="7" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">WBC, per 50-unit increase</td><td align="center" rowspan="1" colspan="1">0.69 (0.52&#x02013;0.90)</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="7" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Age, per 10-year increase</td><td align="center" rowspan="1" colspan="1">0.49 (0.27&#x02013;0.89)</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="7" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>DNMT3A</italic><xref ref-type="table-fn" rid="TFN15">a</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;<italic>R882</italic> mutated vs wild-type</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.85 (1.17&#x02013;2.95)</td><td align="center" rowspan="1" colspan="1">0.009</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;non-R882 mutated vs wild-type</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.92 (0.52&#x02013;1.61)</td><td align="center" rowspan="1" colspan="1">0.76</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="7" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">ELN Genetic Group, Favorable vs Intermediate-I<xref ref-type="table-fn" rid="TFN16">b</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.65 (0.45&#x02013;0.96)</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="7" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>miR</italic>-3151 expression, high vs low</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.51 (1.07&#x02013;2.13)</td><td align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td align="center" colspan="7" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>miR</italic>-155 expression, high vs low</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.47 (1.06&#x02013;2.05)</td><td align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td align="center" colspan="7" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Patients in the ELN modified Favorable Genetic Group<xref ref-type="table-fn" rid="TFN16">b</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="7" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>DNMT3B</italic> expression, high vs low</td><td align="center" colspan="4" rowspan="3" valign="middle">No models including a significant term for <italic>DNMT3B</italic> expression were found</td><td align="center" rowspan="1" colspan="1">1.99 (1.26&#x02013;3.15)</td><td align="center" valign="top" rowspan="1" colspan="1">0.003</td></tr><tr><td align="center" valign="bottom" rowspan="1" colspan="1"><hr/></td><td align="center" colspan="2" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>BAALC</italic> expression, high vs low</td><td align="center" valign="top" rowspan="1" colspan="1">1.81 (1.13&#x02013;2.92)</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td align="center" colspan="7" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Patients in the ELN Intermediate-I Genetic Group<xref ref-type="table-fn" rid="TFN16">b</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="7" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>DNMT3B</italic> expression, high vs low</td><td align="center" colspan="4" rowspan="7" valign="middle">No models including a significant term for <italic>DNMT3B</italic> expression were found</td><td align="center" valign="top" rowspan="1" colspan="1">1.73 (1.10&#x02013;2.72)</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td></tr><tr><td align="center" valign="bottom" rowspan="1" colspan="1"><hr/></td><td align="center" colspan="2" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>BAALC</italic> expression, high vs low</td><td align="center" valign="top" rowspan="1" colspan="1">1.88 (1.05&#x02013;3.35)</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td></tr><tr><td align="center" valign="bottom" rowspan="1" colspan="1"><hr/></td><td align="center" colspan="2" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic>miR</italic>-3151 expression, high vs low</td><td align="center" valign="top" rowspan="1" colspan="1">1.79 (1.05&#x02013;3.07)</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td></tr><tr><td align="center" valign="bottom" rowspan="1" colspan="1"><hr/></td><td align="center" colspan="2" valign="bottom" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WBC, per 50-unit increase</td><td align="center" valign="top" rowspan="1" colspan="1">1.16 (1.01&#x02013;1.33)</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td></tr></tbody></table><table-wrap-foot><fn id="TFN14" fn-type="abbr"><p id="P55">Abbreviations: CI, confidence interval; ELN, European LeukemiaNet; HR, hazard ratio; OR, odds ratio; WBC, white blood count.</p><p id="P56">An odds ratio less than 1 means a lower CR rate for the higher values of the continuous variables and the first category listed for the categorical variables. A hazard ratio greater than 1 (less than 1) corresponds to a higher (lower) risk of an event for higher values of continuous variables and the first category listed of a dichotomous variable. Variables were considered for inclusion in the multivariable models if they had a univariable <italic>P</italic>-value of &#x02264;0.20. See the Supplementary Information for a full list of variables evaluated in univariable analyses. Since <italic>NPM1</italic>, <italic>FLT3</italic>-ITD, and <italic>CEBPA</italic> mutations are integrated in the ELN genetic classification, they were not additionally considered as individual variables. In the entire patient cohort, variables considered for inclusion in the model for achievement of CR were <italic>DNMT3B</italic>, <italic>ERG</italic>, <italic>BAALC</italic>, <italic>miR-155</italic> and <italic>miR-3151</italic> expression, ELN Genetic Groups, <italic>WT1</italic> and <italic>ASXL1</italic> mutation status, WBC, age and extramedullary involvement. In the model for DFS, we considered <italic>DNMT3B, ERG, BAALC</italic> and <italic>miR-3151</italic> expression, ELN Genetic Groups, <italic>FLT3</italic>-TKD, <italic>ASXL1</italic>, <italic>DNMT3A</italic>-R882 and <italic>DNMT3A</italic> non-R882 mutation status and extramedullary involvement; and in the model for OS, <italic>DNMT3B</italic>, <italic>ERG</italic>, <italic>BAALC, miR-155</italic> and <italic>miR-3151</italic> expression, ELN Genetic Groups, <italic>MLL</italic>-PTD, <italic>WT1</italic>, <italic>ASXL1</italic>, <italic>DNMT3A</italic>-R882 and <italic>DNMT3A</italic> non-R882 mutation status, WBC and extramedullary involvement. For patients in the modified Favorable ELN Genetic Group, variables considered for inclusion in the model for OS were <italic>DNMT3B</italic>, <italic>ERG</italic>, <italic>BAALC</italic> and <italic>miR-155</italic> expression, <italic>ASXL1</italic> and <italic>TET2</italic> mutation status and extramedullary involvement. For patients in the Intermediate-I ELN Genetic Group, variables considered for inclusion in the model for OS were <italic>DNMT3B</italic>, <italic>ERG, BAALC, miR-155</italic> and <italic>miR-3151</italic> expression, <italic>RUNX1, IDH1, DNMT3A</italic>-R882 and <italic>DNMT3A</italic> non-R882 mutation status, and WBC and hemoglobin.</p></fn><fn id="TFN15"><label>a</label><p id="P57">The types of <italic>DNMT3A</italic> mutations detected in our cohort are provided in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table S2</xref>.</p></fn><fn id="TFN16"><label>b</label><p id="P58">The ELN modified Favorable Genetic Group is defined as CN-AML patients with mutated <italic>CEBPA</italic> and/or mutated <italic>NPM1</italic> without <italic>FLT3</italic>-ITD. All remaining CN-AML patients (i.e., those with wild-type <italic>CEBPA</italic> and wild-type <italic>NPM1</italic> with or without <italic>FLT3</italic>-ITD, or mutated <italic>NPM1</italic> with <italic>FLT3</italic>-ITD) belong to the ELN Intermediate-I Genetic Group.<sup><xref rid="R47" ref-type="bibr">47</xref></sup></p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float" orientation="portrait"><label>Table 4</label><caption><p id="P59">Gene Ontology terms associated with differentially expressed genes in the high <italic>DNMT3B</italic> expression group</p></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Biologic process or cellular component</th><th align="center" rowspan="1" colspan="1">Number of<break/>genes</th><th align="center" rowspan="1" colspan="1">Benjamini<break/>P-value</th></tr></thead><tbody><tr><td align="center" colspan="3" rowspan="1">Associations with genes upregulated in the high <italic>DNMT3B</italic> expression group</td></tr><tr><td align="center" colspan="3" rowspan="1">Annotation Cluster 1.</td></tr><tr><td align="left" rowspan="1" colspan="1">GOTERM_BP: nucleotide biosynthetic process</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">0.098</td></tr><tr><td align="left" rowspan="1" colspan="1">GOTERM_BP: nucleobase, nucleoside and nucleotide biosynthetic process</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">0.066</td></tr><tr><td align="left" rowspan="1" colspan="1">GOTERM_BP: nucleobase, nucleoside, nucleotide and nucleic acid biosynthetic process</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">0.066</td></tr><tr><td align="center" colspan="3" rowspan="1">Associations with genes downregulated in the high <italic>DNMT3B</italic> expression group</td></tr><tr><td align="center" colspan="3" rowspan="1">Annotation Cluster 1</td></tr><tr><td align="left" rowspan="1" colspan="1">GOTERM_CC: vacuole</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">0.0052</td></tr><tr><td align="left" rowspan="1" colspan="1">GOTERM_CC: lytic vacuole</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">GOTERM_CC: lysosome</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">0.012</td></tr><tr><td align="center" colspan="3" rowspan="1">Annotation Cluster 2</td></tr><tr><td align="left" rowspan="1" colspan="1">GOTERM_BP: endocytosis</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">0.0091</td></tr><tr><td align="left" rowspan="1" colspan="1">GOTERM_BP: membrane invagination</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">0.0091</td></tr><tr><td align="left" rowspan="1" colspan="1">GOTERM_BP: membrane organization</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">0.089</td></tr><tr><td align="center" colspan="3" rowspan="1">Annotation Cluster 3</td></tr><tr><td align="left" rowspan="1" colspan="1">GOTERM_CC: intrinsic to membrane</td><td align="center" rowspan="1" colspan="1">74</td><td align="center" rowspan="1" colspan="1">0.028</td></tr></tbody></table><table-wrap-foot><fn id="TFN17" fn-type="abbr"><p id="P60">Abbreviations: GO, Gene Ontology, see also Huang da <italic>et al</italic>.<sup><xref rid="R45" ref-type="bibr">45</xref></sup>; BP, biologic process; CC, cellular component.</p></fn></table-wrap-foot></table-wrap></floats-group></article>